CD Biosynsis provides a premier platform for N-terminal Specific PEGylation, a sophisticated site-specific conjugation strategy designed to enhance the therapeutic index of proteins and peptides. Unlike conventional random PEGylation which targets multiple lysine amino residues and results in highly heterogeneous mixtures, N-terminal targeting exploits the unique pKa properties of the alpha-amino group. By precisely attaching a single polyethylene glycol (PEG) chain to the N-terminus, we generate homogeneous conjugates that maintain structural integrity, exhibit predictable pharmacokinetics, and meet the stringent regulatory requirements for modern biopharmaceuticals.
Our technical team utilizes high-purity PEG-aldehyde reagents and a meticulously controlled pH environment, typically between 5.0 and 6.0, to achieve site-selectivity exceeding 95 percent. This approach ensures that the lysine side chains remain protonated and non-reactive during the coupling process. Whether you are working with fragile cytokines, growth factors, or complex enzymes, our end-to-end service covers everything from initial feasibility assessment and reagent screening to high-resolution characterization of the final purified conjugate, ensuring your molecule retains maximal bioactivity while gaining superior stability.
Get a QuoteThe chemical foundation of N-terminal specificity lies in the fundamental acidity difference between amino groups. The N-terminal alpha-amino group typically possesses a pKa of approximately 7.6 to 8.0, whereas the epsilon-amino groups of lysine residues have a pKa of 10.0 to 10.5. By performing the reaction in a slightly acidic buffer, the N-terminal group remains significantly deprotonated and nucleophilic, while the lysine residues are safely masked by protonation.
This positional control is critical for maintaining the protein native conformation. Since the N-terminus is often located on the surface and distal to the active site or receptor-binding domain, PEGylation at this site rarely interferes with the protein biological function. Our platform integrates high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) and peptide mapping to confirm 100 percent positional fidelity, eliminating the positional isomers that plague traditional conjugation methods and complicate downstream regulatory filings.
Chemical Mechanism
In a pH 5.0 to 6.0 buffer, the PEG-aldehyde reacts with the N-terminus to form a Schiff base, which is then reduced by sodium cyanoborohydride to form a stable secondary amine bond.
Charge Preservation
Unlike acylation, this method maintains the positive charge of the N-terminal amino group, which is often vital for protein solubility and isoelectric point stability.
PEG-NHS Esters
Utilizing N-hydroxysuccinimide (NHS) active esters under highly controlled kinetic conditions. While more reactive than aldehydes, acylation creates a permanent amide bond.
Peptide Mimicry
This method effectively mimics a natural peptide bond, making it suitable for proteins that require extreme chemical stability in serum environments.
Ketone handle
Using reagents like pyridoxal-5-phosphate to convert the N-terminal amino group into a reactive ketone or aldehyde handle.
Oxime Ligation
The modified handle is reacted with an aminooxy-PEG to form an oxime linkage, providing an orthoganol chemistry route for proteins with sensitive lysine residues.
We apply a rigorous Design-Build-Test pipeline to ensure every PEG-conjugate meets the highest purity and bioactivity standards.
1. Computational Feasibility
2. Reaction Optimization
3. Advanced Purification
4. Structural Validation
Assessment of N-terminal accessibility using 3D structural modeling. Verification of the absence of N-terminal modifications and prediction of the optimal reaction pH based on the local environment.
Small-scale screening of PEG molecular weights and architectures like linear, branched, or Y-shape. Optimization of molar ratios and reducing agent concentrations to maximize yield.
Confirming purity via SDS-PAGE and SEC-HPLC. Site-specific confirmation via enzymatic digestion followed by LC-MS/MS peptide mapping. Bioactivity assay to ensure therapeutic potency is maintained.
Unmatched Homogeneity
Eliminate positional isomers and batch-to-batch variability, providing a single, well-defined molecular entity for regulatory filings.
Activity Preservation
N-terminal sites are typically distal to active pockets, minimizing steric hindrance and ensuring the protein native function is preserved.
State-of-the-Art Analysis
Access to high-resolution orbitrap mass spectrometry and automated peptide mapping to prove site-specificity definitively.
Broad PEG Portfolio
Select from an extensive library of activated PEG derivatives with diverse lengths and branching to fine-tune your molecule half-life.
1. Why is pH so critical in N-terminal specific PEGylation?
Specificity depends on the pKa difference between the N-terminal amine and lysine amines. At pH 5.5, the N-terminus is reactive while lysines are mostly protonated, creating a high reactivity window for the N-terminus.
2. Can this method be used for proteins expressed in mammalian cells?
Yes, but with caution. Many eukaryotic proteins are N-acetylated during post-translational modification. We perform a preliminary analysis to check for blocked N-termini before proceeding.
3. Does N-terminal PEGylation affect the isoelectric point?
Reductive alkylation using PEG-aldehyde preserves the positive charge of the amine, resulting in minimal change to the pI. Acylation neutralizes the charge, which may slightly shift the pI.
4. How do you remove unreacted PEG from the final conjugate?
We utilize ultrafiltration or diafiltration for initial removal, followed by Size Exclusion Chromatography or Ion Exchange Chromatography to ensure the final product is free of free polymer chains.
5. What reducing agents are used and do they affect disulfide bonds?
We primarily use sodium cyanoborohydride. At the acidic pH levels used for N-terminal targeting, this reagent specifically reduces the Schiff base without disrupting stable disulfide bridges in the protein backbone.
6. What is the typical reaction yield for N-terminal PEGylation?
Depending on the protein accessibility, we typically observe mono-PEGylation yields of 60 percent to 85 percent in crude reaction mixtures, which are subsequently purified to high levels.
7. Is it possible to perform N-terminal PEGylation on peptides?
Absolutely. N-terminal PEGylation is a standard method to protect peptides from enzymatic degradation, thereby significantly increasing their metabolic stability in vivo.
8. How do you verify the site-specificity of the PEG attachment?
We employ proteomics techniques where we digest the conjugate and use mass spectrometry to identify the N-terminal peptide fragment, which shows a characteristic mass shift while other fragments remain unchanged.
Do you need a structural accessibility report for your protein, or would you like to discuss the optimal PEG molecular weight for your specific half-life extension goals?
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.